Take­da boots a top prospect out of its late-stage pipeline while an­oth­er is de­layed by war, lock­down

Take­da CEO Christophe We­ber is putting the last of the debt from the Shire deal to bed now, look­ing to grow sales from new launch­es and deal with a drop in prof­its as its big Vy­vanse fran­chise teeters on the edge of gener­ic com­pe­ti­tion.

But while the ex­ecs to­day high­light­ed the plan go­ing for­ward, the small print in the quar­ter­ly re­view in­clud­ed more trou­bling set­backs for its pipeline.

TAK-609, one of the top drugs Take­da boast­ed of from the big Shire buy­out, is fi­nal­ly get­ting the boot af­ter “years of ex­ten­sive reg­u­la­to­ry dis­cus­sions,” the com­pa­ny re­vealed in their look at fis­cal 2021 num­bers. Ac­cord­ing to Take­da:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER